Amylyx Pharmaceuticals AMLX
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Amylyx Pharmaceuticals (AMLX) Business Model and Operations Summary
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Key Insights
Amylyx Pharmaceuticals (AMLX) Stock Information & Key Business Metrics
Latest Closing Price
$12.18Market Cap
$1.15 BillionAverage Daily Volume
1,743,181 Shares52-Week Range
$2.60-$16.96Price-Earnings Ratio
-6.80Total Outstanding Shares
89.17 Million SharesCEO
Joshua B. CohenTotal Employees
123Current Dividend
$0.42 Per Share QuarterlyIPO Date
January 7, 2022SIC Description
Pharmaceutical PreparationsHeadquarters
43 Thorndike Street, Cambridge, MA, 02141